IP Library Granted Patent US 9,808,444
Granted Patent B2
US 9,808,444 · App. 15/341,839 · Granted Nov 7, 2017

Methods for restoration of histamine balance

Inventor: Cristian Arnou (Santa Monica, CA)
Assignee: BioHealthonomics Inc.
A61K31/417A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,808,444
App. No.
15/341,839
Granted
Nov 7, 2017
Kind
B2
Abstract

Several embodiments provided herein relate to histamine dosing regimens are and uses of such regimens in the restoration of histamine balance in subjects suffering from, for example, histapenia and/or histadelia. Several embodiments also relate to the use of histamine dosing regimens for the treatment and/or prevention of migraine headaches.

Claims (24)

1. An escalating histamine dosing regimen comprising in sequential order:

a) a first dosing segment comprising two or more sequential doses of histamine separated by one or more equal time intervals (the “first time interval”), wherein the doses increase in histamine concentration from dose to dose while the administered volume of each dose stays constant; and

b) a second dosing segment comprising two or more sequential doses of histamine separated by one or more equal time intervals (the “second time interval”), wherein the doses increase in histamine concentration from dose to dose while the administered volume of each dose stays constant;

wherein the volume of each histamine dose in the second dosing segment is greater than the volume of each histamine dose in the first dosing segment, and the second time interval is longer than the first time interval.

2. The escalating histamine dosing regimen of claim 1 , further comprising at least a third dosing segment comprising two or more sequential doses of histamine separated by one or more equal time intervals (the “third time interval”), wherein the doses increase in histamine concentration from dose to dose while the administered volume of each dose stays constant.

3. The escalating histamine dosing regimen of claim 1 , wherein the escalating histamine dosing regimen normalizes an activity of one or more histamine receptors, thereby restoring histamine balance.

4. The escalating histamine dosing regimen of claim 3 , wherein the restoration of histamine balance treats one or more of histadelia, histapenia, migraine headaches, Parkinson's Disease, Alzheimer's Disease, amyotrophic lateral sclerosis and epilepsy.

5. The escalating histamine dosing regimen of claim 3 , wherein the restored histamine balance leads to a reduction in frequency and/or intensity of migraine headaches.

6. The escalating histamine dosing regimen of claim 1 , wherein the first time interval results in an administration frequency of between one and four times per week.

7. The escalating histamine dosing regimen of claim 6 , wherein the second time interval results in an administration frequency of between one and six times per month.

8. The escalating histamine dosing regimen of claim 1 , wherein the doses are delivered via a route selected from the group consisting of subcutaneous injection, intravenous injection, intraarterial injection, intramuscular injection, oral delivery, transdermal delivery, sublingual delivery, infusion, suppository, and inhalation delivery.

9. The escalating histamine dosing regimen of claim 1 , wherein the two or more sequential doses of histamine in each dosing segment is administered within a total time frame of less than about five minutes.

10. An escalating histamine dosing regimen comprising in sequential order:

a) a first dosing segment comprising two or more sequential doses of histamine separated by one or more equal time intervals (the “first time interval”), wherein the doses increase in histamine concentration from dose to dose while the administered volume of each dose stays constant; and

b) a second dosing segment comprising two or more sequential doses of histamine separated by one or more equal time intervals (the “second time interval”), wherein the doses increase in histamine concentration from dose to dose while the administered volume of each dose stays constant;

wherein the volume of each histamine dose in the second dosing segment is substantially equal to the volume of each histamine dose in the first dosing segment, and the second time interval is longer than the first time interval.

11. The escalating histamine dosing regimen of claim 10 , further comprising at least a third dosing segment comprising two or more sequential doses of histamine separated by one or more equal time intervals (the “third time interval”), wherein the doses increase in histamine concentration from dose to dose while the administered volume of each dose stays constant.

12. The escalating histamine dosing regimen of claim 10 , wherein the escalating histamine dosing regimen normalizes an activity of one or more histamine receptors, thereby restoring histamine balance.

13. The escalating histamine dosing regimen of claim 12 , wherein the restoration of histamine balance treats one or more of histadelia, histapenia, migraine headaches, Parkinson's Disease, Alzheimer's Disease, amyotrophic lateral sclerosis and epilepsy.

14. The escalating histamine dosing regimen of claim 12 , wherein the restoration of histamine balance leads to a reduction in frequency and/or intensity of migraine headaches.

15. The escalating histamine dosing regimen of claim 10 , wherein the first time interval results in an administration frequency of between one and four times per week.

16. The escalating histamine dosing regimen of claim 15 , wherein the second time interval results in an administration frequency of between one and six times per month.

17. The escalating histamine dosing regimen of claim 10 , wherein the doses are delivered via a route selected from the group consisting of subcutaneous injection, intravenous injection, intraarterial injection, intramuscular injection, oral delivery, transdermal delivery, sublingual delivery, infusion, suppository, and inhalation delivery.

18. The escalating histamine dosing regimen of claim 10 , wherein the two or more sequential doses of histamine in each dosing segment is administered within a total time frame of less than about five minutes.

Assignments (2)
CHANGE OF NAME Recorded May 10, 2021
From: BIOHEALTHONOMICS, INC.
To: AGONEX BIOPHARMACEUTICALS, INC. (CA)
Reel/Frame 056184/0083 →
MERGER Recorded May 10, 2021
From: AGONEX BIOPHARMACEUTICALS, INC. (CA)
To: AGONEX BIOPHARMACEUTICALS, INC. (DE)
Reel/Frame 056184/0201 →
Continuity (7)
Continuation 14684174 · Apr 10, 2015
Continuation 14315206 · Jun 25, 2014
Continuation In Part PCTUS2013046420 · Jun 18, 2013
Provisional Application 61733630 · Dec 5, 2012
Provisional Application 61867966 · Aug 20, 2013
Provisional Application 62002613 · May 23, 2014
Related Publication 20170266163A1 · Sep 21, 2017